STAGE IV PROSTATE CANCER AJCC V8

This early-phase trial tested whether adding a chemotherapy drug (decitabine/cedazuridine) to the standard drug enzalutamide could help men with metastatic castration-resistant prostate cancer whose cancer had stopped responding to enzalutamide alone. Only 8 men were enrolled bef…

This phase 2 trial tested the drug erdafitinib in 11 men with castration-resistant prostate cancer that had spread to the bone. The study aimed to see if erdafitinib could slow cancer growth by blocking certain enzymes. Researchers also collected blood and bone marrow samples to …

This study tested a combination of two drugs, apalutamide and abiraterone, along with prednisone, in men whose prostate cancer had spread and stopped responding to standard hormone therapy. The goal was to see if this combination could slow cancer growth. Only 7 men took part bef…

This study tested a precision medicine approach for people with advanced cancers like breast, ovarian, pancreatic, prostate, or sarcoma. Researchers used genetic and protein tests to track how the cancer changes and then a team of experts recommended personalized drugs. The goal …

This study tested a new imaging agent called 68Ga-PSMA-11 to see if it could give clearer pictures of where prostate cancer has spread in men with advanced, treatment-resistant disease. The goal was to help doctors better understand the location of tumors. The study was terminate…

This study tested a radioactive drug called Sn-117m-DTPA to see if it could reduce bone pain in men with prostate cancer that had spread to their bones and no longer responded to hormone therapy. Only one person enrolled before the study was stopped. The goal was to measure pain …

This study offered genetic testing to men whose prostate cancer had spread to other parts of the body. Researchers looked for inherited gene changes linked to cancer risk and asked participants about their thoughts on testing. The goal was to learn if this approach works well and…